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Abstract
Background:  It is generally acknowledged that a disparity between knowledge and its
implementation is adversely affecting quality of care. An example commonly cited is the failure of
clinicians to follow clinical guidelines. A guiding assumption of this view is that adherence should be
gauged by a standard of conformance. At least some guideline developers dispute this assumption
and claim that their efforts are intended to inform and assist clinical practice, not to function as
standards of performance. However, their ability to assist and inform will remain limited until an
alternative to the conformance criterion is proposed that gauges how evidence-based guidelines
are incorporated into clinical decisions.
Methods: The proposed investigation has two specific aims to identify the processes that affect
decisions about incorporating clinical guidelines, and then to develop ad test a strategy that
promotes the utilization of evidence-based practices. This paper focuses on the first aim. It presents
the rationale, introduces the clinical paradigm of treatment-resistant schizophrenia, and discusses
an exemplar of clinician non-conformance to a clinical guideline. A modification of the original study
is proposed that targets psychiatric trainees and draws on a cognitively rich theory of decision-
making to formulate hypotheses about how the guideline is incorporated into treatment decisions.
Twenty volunteer subjects recruited from an accredited psychiatry training program will respond
to sixty-four vignettes that represent a fully crossed 2 × 2 × 2 × 4 within-subjects design. The
variables consist of criteria contained in the clinical guideline and other relevant factors. Subjects
will also respond to a subset of eight vignettes that assesses their overall impression of the
guideline. Generalization estimating equation models will be used to test the study's principal
hypothesis and perform secondary analyses.
Implications: The original design of phase two of the proposed investigation will be changed in
recognition of newly published literature on the relative effectiveness of treatments for
schizophrenia. It is suggested that this literature supports the notion that guidelines serve a valuable
function as decision tools, and substantiates the importance of decision-making as the means by
which general principles are incorporated into clinical practice.
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Introduction
In their report on translating behavioral science into
action, The National Advisory Mental Health Council
notes: 'At present too few researchers are attempting to
bridge across basic, clinical, and services research, and not
enough are working with colleagues in related allied dis-
ciplines to move research advances out of the laboratory
and into clinical care, service delivery, and policymaking
[1].
What has resulted from this situation might be called the
'dissemination gap' – a disparity between knowledge and
its implementation [2]. A number of investigators have
emphasized that disjunctions between research and appli-
cation [3-5], science and service [6,7], and research and
policy [8] are adversely affecting the quality of public
mental health programs and services. Though such prob-
lems have been appreciated since at least the late 1940s,
the current effort to bridge clinical research and practice
began in earnest in the early 1990s, with the telling words
of Congressman George Brown: 'All the basic science
funding in the world will have no positive effect on the
well-being of our nation if the research is not carried out
within a system that can effectively digest and apply the
results' [9].
The dissemination gap is amply illustrated by complica-
tions of implementing evidence-based practices (EBPs) in
the medical branch of psychiatry. Most psychiatric practi-
tioners acknowledge that clinical decisions and practices
should be based on the best available evidence [10].
Nonetheless, EBPs have not been received with the enthu-
siasm that was anticipated, and a variety of explanations
have been proposed for the apparent anomaly. Even a cur-
sory review of the literature shows that the implementa-
tion of EBPs is a polarizing issue. One group of researchers
tout their importance for quality of care and their rele-
vance to mental health policy [11]. Others retort by warn-
ing practitioners to 'proceed with care!' [12]. They are
concerned about a potentially deleterious effect of EBPs
on quality of care [13] and believe that the implementa-
tion of EBPs is on a collision course with the movement
to individualize care and promote patient-centered
healthcare [14,15].
One of the most frequently expressed reasons for the fail-
ure to adopt EBPs in medicine, particularly psychiatry and
mental health, pertains to the decision-making practices
of clinicians. Studies have shown that lack of adherence to
EBPs is a result of systemic decisional biases [16,17].
These claims can draw support from hundreds of studies
conducted over the past fifty years. Beginning with
Meehl's [18] research that compared clinical with actuar-
ial prediction, and proceeding through the work of Gold-
berg [19], Dawes [20], and others, studies have found
almost universally that clinicians lack the consistency and
the perceptive and integrative power that are requisite to
sound decision-making. In short, they tend be 'subopti-
mal' decision-makers who, as such, perform less capably
than statistical models [21,22].
Perhaps, as Proctor suggests, such broad-based conclu-
sions do little more than identify easy targets and offer
simplistic answers [23]. Nonetheless, lack of endorsement
for EBPs, well-documented resistance on the part of some
clinicians, and their tendencies toward sub-optimal deci-
sion-making lead to three related conclusions: Sound clin-
ical judgment is a predicate of evidence-based medicine;
there is a need for more research on how the implementa-
tion of EBPs is affected by clinical decision-making, and
medical education should give priority to training clini-
cians in how to make good clinical decisions [24-26]. To
lead the effort to understand more fully that factors that
influence the uptake of EBPs and encourage their broader
dissemination, the National Institute of Mental Health
recently advanced a series of organizational and program-
matic initiatives intended to expand the frontier of imple-
mentation research and raise the profile of dissemination
[27]. The proposed study responds to this call.
A useful way to understand the dissemination problem is
through the lens of evidence-based medicine (EBM),
which Sackett and associates define as: 'the conscientious,
explicit, and judicious use of current best evidence in mak-
ing decisions about the care of individual patients' [28]. It
may be tempting to regard EBM as the mere implementa-
tion of policies and procedures, then to gauge their effec-
tiveness by how closely they are followed in clinical
practice. In fact, the relationship between EBM and EBPs
is far richer, and their relevance to clinicians is considera-
bly more complex: EBM uses EBPs to aid clinical judg-
ment. EBPs and clinical guidelines must be employed
conscientiously and incorporated judiciously. For exam-
ple, the American Psychiatric Association's practice guide-
line development process depicts guidelines as 'strategies
to assist psychiatrists in clinical decision-making' [29].
Consider as well the opening statement of the APA's schiz-
ophrenia guidelines: 'This report is not intended to be
construed or to serve as a standard of medical care' [30].
'Incorporation' is the key concept in the preceding pas-
sages. Well-intentioned efforts that equate conformance
to a guideline with its utilization in practice have tended
to exacerbate the very resistance that EBM was seeking to
overcome [31]. Battle lines are drawn when clinicians are
told, in one way or another, that the quality of their work
can be gauged by how closely they conform to guidelines
that were developed for the express purpose of aiding
their decisions rather than directing them [32,33]. Despite
the beneficent objective of improving quality of care, suchImplementation Science 2008, 3:13 http://www.implementationscience.com/content/3/1/13
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efforts tend to polarize and backfire. The study described
here attempts to break this impasse by proposing incorpo-
ration rather than conformance as the principal test of uti-
lization, and developing a strategy that is designed to
encourage clinicians to incorporate EBPs into their prac-
tice. As noted above, guidelines and EBPs are incorporated
into through decision-making. As Patel and associates
contend, 'evidence is invariably perceived evidence in the
physicians' mind' [[34], p. 162], and the diffusion of EBPs
will lead to greater utilization insofar as they fit the cogni-
tive processes of decision-makers [35-37].
This proposed investigation has two specific aims: to iden-
tify the processes that affect decisions about incorporating
clinical guidelines, and then to develop and test a strategy
that promotes the utilization of EBPs. This paper focuses
on the first aim and proceeds in three steps: First, it
describes a preliminary piece of research showing that
psychiatrists fail to adhere to a specific evidence-based
guideline that they are acquainted with and endorse in
principle. Second, it discusses how the appropriate use of
decision theory can facilitate a richer understanding of
these findings. The third step is modify the procedure
employed previously and conduct an empirical investiga-
tion of how the guideline is incorporated into treatment
decisions. This paper describes the proposed methodol-
ogy, including procedures, hypotheses, and the plan for
data analysis. Plans for components two and three,
including the need for modifications that have come to
light subsequent to the protocol's development, are
described in the discussion section of this paper.
Background and significance
Evidence-based practices in psychiatry
It is possible to conduct a general examination of evi-
dence-based practices and their implementation, but not
without overlooking the specialization of knowledge that
pervades medical training, research, and practice. In psy-
chiatry, every major disorder – in some cases, multiple
subcategories within disorders – have distinct practices
and guidelines. The proposed study focuses on the clinical
paradigm of schizophrenia, a severe mental illness that
afflicts over two million Americans [38]. The cause of
schizophrenia has yet to be definitively identified and
aspects of its nature remain mysterious. Nonetheless, sig-
nificant gains have been made, especially over the past
twenty years, in developing effective symptomatic treat-
ments [39]. Along with comprehensive approaches to
service delivery [40], current treatments enable patients to
live independently in the community as they recover from
the illness [41,42].
However, there is a subset consisting of 10 to 30% of
patients who have an inadequate response to antipsy-
chotic medications [30,43]. They comprise the category
known as treatment-resistant schizophrenia (TRS). Stud-
ies have examined the effectiveness of various antipsy-
chotic medications for TRS, including clozapine [44,45]
and other second generation antipsychotics (SGA's, also
known as 'atypical antipsychotics'), either individually or
in combination [46-48]. By and large, these treatments
have demonstrated limited effectiveness, but given the
lack of more efficacious alternatives they nonetheless are
valuable components of the clinical armamentarium.
Although there is little dispute about the importance of
identifying patients who have treatment resistant disor-
ders, there are no universally accepted classification crite-
ria. In general, investigators have adapted criteria initially
advanced by Kane [49], of positive symptoms (delusions,
hallucinations, disorganization) that are not significantly
reduced or adequately remediated following two full trials
of antipsychotic medication. Overall, difficulties of classi-
fication, overall lack of treatment effectiveness, and lack of
consensus over the best course of treatment make TRS a
complex and vexing clinical situation and an attractive
paradigm for studying the role of clinical guidelines in
treatment decision-making.
The general problem of implementing EBPs in the treat-
ment of schizophrenia was amply illustrated by the
response to the Schizophrenia Patient Outcomes Research
Team (PORT) treatment guidelines. These guidelines were
developed from a review of the literature by experts and
widely disseminated in 1998 [50]. Buchanan [51] exam-
ined the records of 224 inpatients and 368 outpatients
with schizophrenia and found a high rate (greater than 95
percent) of conformance with PORT's medication guide-
lines, but low conformance with dosage recommenda-
tions (62 percent for inpatients and 28 percent for
outpatients). These findings were consistent with a previ-
ous finding about medications being used ineffectively,
either at levels below therapeutic dosage or above maxi-
mum recommend dosage [52].
The original PORT guidelines were revised in 2004 [53],
largely in response to the growing literature on the relative
efficacy of first- versus second-generation antipsychotic
medications (FGAs versus SGAs). Despite the initial
enthusiasm that accompanied the approval and release of
SGAs such as risperidone, olanzapine, and ziprasidone, as
a group they appear not to be more effective, at least for
initial or first-break treatment, than the considerably less
expensive FGA's such as haloperidol, perphenazine, and
fluphenazine [54]. Consequently, revised PORT recom-
mended FGAs as the first line of treatment. In addition,
several studies had demonstrated that clozapine, the pro-
totypical SGA, was particularly effective for treatment
resistant schizophrenia [44,55]. The revised PORT guide-
line recommended clozapine treatment for TRS, despiteImplementation Science 2008, 3:13 http://www.implementationscience.com/content/3/1/13
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the difficulties of managing the medication and its poten-
tially severe side effects [56].
Using the revised PORT guidelines as a template, Sernyak
and associates [57] developed an evidence-based guide-
line for TRS, then tested clinician conformance, using cli-
nicians who had been introduced to the guideline,
understood its use, and explicitly concurred with it. The
TRS guideline developed by Sernyak et al. is summarized
in Table 1. It calls for patients to be assessed at the end of
a three-month medication trial, using the Clinical Global
Inventory (CGI) to assess progress and illness severity
[58]. A 'non-responder' was defined as a patient whose
CGI scores indicate at least a moderate mental illness, and
a condition that has either not improved or has deterio-
rated over the course of treatment. Adhering to the guide-
line involves moving one step up the treatment ladder,
beginning another three-month trial, assessing again,
then continuing up the ladder until the patient no longer
meets non-responder criteria. Sernyak and associates
examined the charts of the prescribing physician subjects.
Almost half of their patients with schizophrenia met the
TRS criteria, but for 95 percent of these patients, the phy-
sician elected to maintain the current medication in lieu
of following the TRS guideline.
The findings obtained by Sernyak and associates were
both surprising and expected. On the one hand, they are
consistent with other studies about conformance with the
PORT schizophrenia guidelines [59]. Reasons for depart-
ing from the guideline included the patient's unwilling-
ness to change the current medication, non-adherence to
medications, a current condition of being stable, or the
clinician's judgment that more time is needed with the
current regimen. These reasons are similar to the items
identified in the latest Schizophrenia PORT guidelines as
factors to be considered in choosing an antipsychotic
medication [53]. On the other hand, it is puzzling that in
95 percent of cases failed to conform to the TRS guideline
when clinicians were knowledgeable of the guideline and
concurred with it in principle.
The proposed study examines the apparent anomaly in
how clinicians use the TRS guideline by employing three
principal modifications of the procedure employed by
Sernyak and associates: First, instead of consulting clinical
charts, the proposed study uses case vignettes, which per-
mit a precise manipulation of the factors that influence
treatment decisions, hypothesis testing about their rela-
tive importance, and a descriptive account of decision
strategies.
Second, whereas the Sernyak study used both psychiatric
residents and staff psychiatrists as subjects, the current
study focuses on psychiatric trainees – third-, fourth-, and
fifth-year residents who have experience in treating adults
with disorders in the schizophrenia spectrum. This
approach enables the investigation to identify one specific
group of clinicians where training can have a discernible
effect on decision-making. Studies of pattern learning and
clinical judgment have found that experts and trainees use
different patterns of reasoning [60,61], and that these dif-
ferences affect their use of clinical guidelines [35]. These
findings suggest that even if an experienced psychiatrist
and a resident make the same treatment decision in a
given case, they will go about the task differently. One of
the limitations of previous implementation efforts lies in
their failure to tailor the intervention to a specific audi-
ence and facilitate its dissemination.
Third, the proposed study draws expressly on the tradition
of behavioral decision-making to describe the role of the
TRS guideline in clinicians' decisional processes. The fol-
lowing section discusses this tradition and indicates why
a naturalistic approach to decision-making and a cogni-
tively-rich naturalistic theory has been chosen over the
more customary models that are derived from classical
decision theory.
Decision-making and evidence-based practices
Behavioral decision theory has played a significant role in
medical research and education, and the importance of
decision-making for clinical practice has long been recog-
nized [62-64]. Unfortunately, much of this work has
Table 1: The Guideline for the Treatment Resistant Schizophrenia
Step Treatment Common Examples
1 FGA #1: 1st trial of a first-generation (conventional) 
antipsychotic medication
haloperidol (Haldol), perphenazine (Trilafan), fluphenazine (Prolixin), 
loxapine (Loxitane), molindone (Moban), thiothixene (Navane) 
trifluoperazine (Stelazine)
2 FGA #2: 2nd trial of a first-generation antipsychotic medication as above
3 SGA #1: 1st trial of a second-generation (atypical) antipsychotic 
medication
risperidone (Risperdal), aripiprazole (Abilify), quetiapine (Seroquel), 
olanzapine (Zyprexa), serlect (Sertindole)
4 SGA #2: 2nd trial of a second-generation antipsychotic 
medication
as above
5 Clozapine clozapine (Clozaril) onlyImplementation Science 2008, 3:13 http://www.implementationscience.com/content/3/1/13
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relied on models of classical decision theory (CDT),
which arguably have limited application to the task of
understanding how clinicians make treatment decisions,
particularly under practical constraints such as having
limited information, working with complex disorders that
have heterogeneous outcomes, and prescribing for
patients who have treatment-resistant conditions. The
principal problem with CDT is its all-consuming interest
in making optimal decisions, which putatively result from
the proper employment of a logical model. The normative
thrust of CDT was evident from its origin in the work of
Pascal [65], to the initial forays into behavioral decision-
making by von Neumann and Morgenstern [66], and
later, through models developed by experimental and
social psychologists that have been applied directly to
clinical practice [67,68]. Elstein [69] makes an explicit
link between EBM and CDT by asserting that a treatment
is 'evidence-based' when it has a higher probability of
achieving a desirable outcome than a non-evidence-based
alternative. The guiding notion is that the best clinical
outcome will be attained by choosing the intervention
that maximizes expected value.
These findings and the procedures that led to them have
been questioned on several grounds [70-74]. For one, the
idea of comparing actual with optimal decisions enables
investigators to observe how frequently decision-makers
fall short of an ideal, but a prescriptive focus does not suf-
fice as an explanation of how, where, and why decision-
making goes wrong. This limitation of normative models
is particularly important in clinical education and
research, where the objective is to correct and improve
decision-making, not merely observe that it has fallen
short. Moreover, comparing actual practices against
guidelines implicitly construes the latter as standards of
optimality and involves a test of conformance. It does not
enable investigators to determine whether guidelines have
been incorporated into clinical decision processes. The
difference is particularly important, given that clinicians
can conform to clinical guidelines without understanding
why they should be applied. Concomitantly, an appropri-
ate use of guidelines is to take them into account without
following them in a particular case.
A number of investigators have expressed dissatisfaction
with the inveterate use of normative modeling and
attempted to predicate behavioral decision theory on
more empirical and descriptive grounds. A host of exem-
plary adaptations of CDT have followed, some of which
focus specifically on the decision-making practices of phy-
sicians and other clinicians [75-78]. The best known
exemplar is 'cognitive heuristics,' which Kahneman and
Tversky developed from a series of clever and compelling
studies demonstrating that decision-making is subopti-
mal because people simply do not follow normative strat-
egies [79,80]. This work has won a prominent place in the
decision-making literature, particularly the study of med-
ical decision-making [62,68,81,82]. However, a premise
of this approach is that cognitive short-cuts inevitably lead
to inaccurate judgments, a notion that has been vigor-
ously challenged in a variety of studies, including applica-
tions of clinical decision-making [83,84]. Moreover, the
notion that decision-makers function as transducers, and
employ a cognitive apparatus that works like a choice-
selecting mechanism, is not a desirable or reasonable way
of depicting clinical practice. When decisions are made
with limited information, uncertainties are incalculable,
and there is no universally correct answer, cognition plays
a role more akin to active problem solving than passive
optimizing.
The naturalistic alternative
Some decision researchers contended that CDT should
not be repaired, but supplanted by empirically-based the-
ories, and proceeded to develop the approach known as
Naturalistic Decision-Making (NDM) [85]. The applica-
tion of NDM to medicine was actually pioneered by
Elstein [61,86], who decried the surfeit of anecdotes that
have been inspired by accounts of suboptimal decision-
making and the gratuitous recommendations of what cli-
nicians ought to be doing. The wisdom inspired by CDT
presumes a friction-free environment that fails to appreci-
ate the concrete situations that decision-makers confront,
particularly when they ae working with complex clinical
problems.
Patel and associates built on Elstein's work in several
ways. For them, the persistent gap between knowledge
and its implementation is a result of failing to understand
how information contributes to knowledge, and how the
gap between knowledge and information can be
addressed by focusing on the cognitive processes of mak-
ers [34,35]. These investigators, along with other propo-
nents of a cognitive-rich naturalistic approach to clinical
decision-making, are suspicious of initiatives 'that pro-
mote blind adherence to a course of action without target-
ing the understanding in any meaningful sense' [73].
One of the most prolific advocates of NDM in cognitive
and organizational psychology is Lee Beach, who began
working on a naturalistic alternative after devoting his
early career to the study of classical theory. In addition to
issuing a protracted critique of CDT [87], Beach devel-
oped Image Theory (IT), which is one of the most fully
articulated and extensively researched of all the NDM-
inspired theories [87-89]. A distinctive feature of IT is that
it posits that decision-making involves the simple applica-
tion of multiple strategies, in contrast to CDT, which pos-
its that decision-making involves complex applications of
a single strategy.Implementation Science 2008, 3:13 http://www.implementationscience.com/content/3/1/13
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For IT, decision processes begin with winnowing or filter-
ing out unacceptable alternatives, and only if necessary
proceeding to a second stage of choosing a preferred alter-
native [90,91]. The mechanism of discarding unaccepta-
ble alternatives is called screening. Much of the time,
decisions are made simply or principally by excluding
alternatives that are incompatible with internally-gener-
ated criteria. For example, the choice of where to eat lunch
is based on proximity, cost, health, and taste. Restaurants
are excluded or 'screened out' that are too far away, too
expensive, or serve food that is unhealthy or unpleasant.
Each instance of a disjunction between attribute and crite-
rion counts as a 'violation', and options are discarded
whose violation count exceeds an arbitrary critical
number known as the 'rejection threshold' [92,93]. In the
example above, one may reject restaurants that fail at least
two attributes, but those that fail none or only one remain
as candidates for a subsequent selection procedure.
Two distinctive characteristics of screening concern the
weighting of attributes and the consistency of the rejec-
tion threshold. IT studies have shown that the most com-
mon screening strategy involves unit-weighting [92,94].
In that event, alternatives are excluded simply by the vio-
lation count: If the four criteria of restaurants are regarded
as equally important, then those whose violations exceed
the rejection threshold are screened out, regardless of
which specific criteria are violated. With differential
weighting, certain violations are regarded as more impor-
tant than others. For instance, proximity may have twice
the value of cost, unhealthiness may be three times as
important as proximity, etc. [94].
Findings from IT research indicate that screening and
choice are distinct decision strategies that occur in
sequence. If more than one candidate survives the screen-
ing stage, a choice will be made invoking a more exhaus-
tive procedure. Identical criteria can be utilized in both
phases, but studies have shown that they are weighed and
aggregated differently [95]. Commonly, screening elimi-
nates all candidates except one and therefore becomes
determinative. For instance, consider that most treatment
decisions are binomial: Providers either continue the cur-
rent treatment or switch to another therapy. If we assume
that this decision is made by means of a choice strategy,
then it would involve an exhaustive comparison of alter-
native treatments. If instead, the decision is to continue
current treatment unless there are specific reasons to reject
it – or if the decision is to follow a treatment guideline
unless there are specific reasons not to – then screening is
the definitive decision strategy.
It is suggested that clinicians incorporate EBPs into their
decisional processes through the mechanism of screening.
Instead of, or at least prior to, their using a guideline to
assist in making a choice, they assess the guideline's appli-
cability to the case at hand by using pertinent clinical facts
as screening criteria. Thus, when the clinicians in the Sern-
yak study reported reasons for departing from the guide-
line that included the patient's unwillingness to change
the current medication, non-adherence, the stability of
the current condition, or the need for more time to evalu-
ate treatment response, they were saying, in effect: I will
follow the TRS guideline unless there is sufficient reason
not to follow it. I may determine that the guideline is not
appropriate for a given case. If so, my decision in this
instance does not represent a wholesale rejection. Even if
the guideline does not survive to the end of my decisional
process, it played a crucial role at the beginning. The pro-
posed study examines whether indeed psychiatric resi-
dents are applying a screening strategy to the TRS
guideline; if so, whether they are weighing violations
equally, following a consistent rejection threshold, or
operating in a more incremental fashion.
Methods
Study population, subjects, and recruitment
Twenty volunteer subjects will be recruited from the pop-
ulation of third-, fourth-, and fifth-year residents in an
accredited psychiatry training program who are currently
treating or have recently treated adults who have schizo-
phrenia or schizo-affective disorder. The study will not use
first-and second-year residents, who either lack sufficient
knowledge about diagnosis and treatment to make inde-
pendent clinical decisions, or lack experience in working
with a severely mentally ill population. Given the institu-
tional affiliation of the principal investigator and the
funding source, study protocols and consent forms will be
approved by three Human Investigation Committees.
The protocols call for subjects to be recruited passively
through general announcements, advertisements in com-
mon resident areas, through the department listserv, and
by word-of-mouth. It is essential that participation be
regarded as entirely voluntary and minimize the possibil-
ity that candidates might feel pressure to participate.
Efforts will be made to ensure that participation is neither
encouraged nor required by the residency program, that
no one associated with the program would see individual
study data, and that the study would not be used to assess
their progress. The study task requires about one hour and
subjects will be paid $100 for participating.
Procedures, instruments, and design
Subjects will be handed a loose leaf binder containing the
two consent forms, a registration form, general informa-
tion about treatment-resistant schizophrenia and the TRS
guideline, and the study stimulus. Subjects can consult
this information at any time. The stimulus consists of 72
vignettes that pertain to a hypothetical 24 year old maleImplementation Science 2008, 3:13 http://www.implementationscience.com/content/3/1/13
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with schizophrenia. The vignettes will be presented
sequentially in three groups: The first 32 pertain to step
two of the guideline; the second 32 pertain to step four,
and the other eight are designed to test the subject's expec-
tation about the general effectiveness of the guideline. The
same set of vignettes appear in both step two and step
four. The final eight are drawn systematically from the 32,
as described below. The order of items in each of the three
sets will be randomized into four stimulus groups (in no
case will the order of the vignettes in steps two and four
correspond). Subjects will receive one of the four groups
at random.
The 32 vignettes for steps two and four represent all com-
binations of a 2 × 2 × 2 × 4 design:
Progress
Two levels, representing a score of four or six on the Clin-
ical Global Inventory (CGI, the instrument used to assess
treatment resistance). A score of six indicates a lack of suf-
ficient progress and is a criterion of treatment resistance.
A score of four indicates sufficient progress to disqualify
the patient from moving to the next step.
Condition
Two levels, representing a score of three or seven on the
CGI, where seven indicates an unacceptable low level of
functioning and a criterion of treatment resistance, and
three indicates sufficient progress to disqualify the patient
from moving to the next step.
Adherence to antipsychotic medications
Two levels, operationally defined as a rate of 25% (low
adherence) or 75% (high adherence).
Progress forecast
Four expected outcomes if the guideline were to be fol-
lowed in this case:
Ineffective: 10% likelihood of significant improvement,
80% likelihood of no significant change, and 10% likeli-
hood of decompensation;
High risk: 45% likelihood of significant improvement,
10% likelihood of no change, 45% likelihood of decom-
pensation;
Low gain: 10% likelihood of significant improvement,
40% likelihood of no change, 50% likelihood of decom-
pensation.
High gain: 50% likelihood significant improvement, 40%
likelihood of no change, 10% likelihood of decompensa-
tion.
Violations
For the purpose of the study, a violation is a clinical factor
that is either inconsistent with the guideline or a reason to
depart from it. The lower scores in factors one and two
above indicate that the patient is responding sufficiently
to current treatment and does not meet the TRS criteria.
Low adherence and poor forecasted progress do not
appear in the guideline, but nonetheless serve as poten-
tially powerful reasons not to recommend a medication
change. A good forecast is high gain (forecast four, above);
ineffective, high risk, or low gain forecasts are all regarded
as poor. For the 32 vignettes, one had no violations, six
vignettes had one, twelve had two, ten had three, and
three vignettes had four violations. The subset of eight
vignettes are used to inquire about step three of the TRS
guideline and consist of factors two and three, and fore-
casts three and four. (The progress factor will be held con-
stant at six, which is not a violation of the guideline). Of
the eight vignettes, one has 0 violations, three vignettes
have one, three have two violations, and one vignette has
three.
Data collection, hypotheses, and data analysis
For the 32 case vignettes at steps two and four of the TRS
guideline, subjects will indicate whether they would pro-
ceed to the next step of the guideline or not, then rate their
confidence in the decision on a seven-point scale that
ranges from extremely confident to not confident at all.
For the eight vignettes at step three, subjects will make
three ratings, each as a percentage from zero to 100: the
likelihood that following the protocol will ever result in a
good treatment response; the likelihood that the patient
will ever have a good response by not following the pro-
tocol, and the likelihood that the clinician would follow
the step four of the guideline after an insufficient response
at step three. Data will also be collected on subject gender,
age, race, ethnicity, and year in the residency program.
Hypotheses will be tested using the General Estimating
Equation (GEE) algorithm in SPSS version 15 [96]. GEE
models are appropriate for measuring the magnitude of
association for dichotomous correlated outcomes, which
commonly are encountered in repeated-measures or
within-subjects designs [97]. GEE models have become
popular in mental health services research, owing to the
importance of acknowledging interdependence of crite-
rion variables, as well as greater availability of statistical
software [98,99] GEE permits models to be examined for
overall significance and for the significance of individuals
main effects and interaction, using the Wald test [100].Implementation Science 2008, 3:13 http://www.implementationscience.com/content/3/1/13
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Principal Hypothesis: Subjects incorporate the TRS 
guideline into their treatment decisions via a unit-weighted 
screening strategy
In a screening strategy, the number of violations is deter-
minative and specific violations, both individual and in
relationship to one another, are irrelevant. With unit-
weighting, each violation is equally important. Thus, the
study hypothesis is that a greater number violations is
associated with a greater likelihood of rejection. We will
test whether a summary score containing the total number
of violations predicts rejection of the guideline. Follow-up
analysis will evaluate whether there is evidence of a 'rejec-
tion threshold' – an hypothesized point at which viola-
tions exceed an arbitrary standard. For this analysis we
will compare, Bonferroni protected, each sum of viola-
tions against zero violations. This analysis will be fol-
lowed by testing each sum against the level immediately
below it (two violations versus one, three violations ver-
sus two, four violations versus three). The pattern of sig-
nificant and non-significant effects will provide
information on where the rejection threshold(s) occurs.
Unit-weighting predicts that each of the four violations –
progress, condition, adherence, and forecast – will have a
similar effect on outcome. For the second test of the unit-
weighting hypothesis, we will evaluate the impact of each
violation based on the rejection threshold. That is, if the
rejection threshold is one, each violation type should be
significantly associated with rejection. If the rejection
threshold is two, all two-violation combinations should
significantly predict rejection.
Secondary analyses
As this study is exploratory, it relies on descriptive and
post-hoc analyses to inform the investigators about the
processes that effect subjects' decisions to endorse or reject
the TRS guideline. Consequently, we will examine the
influence of the individual factors that are manipulated in
the study design. The general strategy is to begin by focus-
ing on the three variables – 'step,' 'forecast,' and 'adher-
ence' – that are not TRS guideline criteria, but nonetheless
may constitute screening strategy violations. Following
these analyses, we will inquire into whether – and if so,
how – subjects endorse the guideline by examining the
two TRS criteria, 'progress' and 'condition.'
Secondary analyses will also evaluate alternatives to unit
weighting, including non-unit weighted screening, con-
tingency models [101], and Recognition Primed Deci-
sion-making [102,103]. The latter two approaches are
applications of naturalistic decision-making that may be
particularly useful if subjects endorse the guideline under
certain conditions and not others, or if there are identifia-
ble subsets of subjects who are more inclined than others
to endorse the guideline. Secondary analyses will create
models that evaluate the violations as main effects and
interactions and compare treatment decisions with confi-
dence assessments. Since these analyses are exploratory,
we will rely on Pan's extensions of Akaike's information
criterion (AIC) test [104] to compare models for good-
ness-of-fit.
Discussion
It is anticipated that proposed study will affirm the value
of examining how cognitive processes of clinicians effect
their treatment decisions. In addition, it may lead to
broader application of an incorporation test for clinical
guidelines. Its first application is in developing a strategy
that increases the implementation of evidence-based prac-
tices by assisting clinicians in how to make complex treat-
ment decisions. This approach may prove more effective
than adherence-based dissemination programs or proce-
dures that may be more appropriate for classic cases than
for what clinicians commonly encounter in consulting
rooms, medication clinics, and community treatment
facilities.
Originally, the study called for phase two to duplicate the
methods described here, using different variables. Signifi-
cant developments that occurred after the project was con-
ceived and funded have led to modifying the original
plan. The TRS guideline has had a limited shelf life, and
been supplanted by another guideline [105]. Meanwhile,
one of the key assumptions of both the old and new
guidelines is that FGAs should be first-line treatments.
Recent studies have called this assumption into question
[39,106,107]. After careful consideration, it was decided
that phase two will use the Texas Medication Algorithm,
Schizophrenia Module (TMA) [108], a guideline that dif-
fers from TRS in several respects. Besides using SGAs as
first-line treatments, TMA calls for earlier implementation
of clozapine therapy and the use of adjunctive treatments.
It contains a validated measure of progress and employs
three categories of response – full, partial, and non-
response [109]. The latter feature is particularly important
because it enables phase two to examine partial responses,
which require clinician discretion and are more conducive
to a standard of incorporation than adherence.
Changes in guidelines for the treatment of schizophrenia,
particularly TRS, were inevitable, given the sweep of
events that has followed completion of the first phase of
the Clinical Antipsychotic Trials of Intervention Effective-
ness (CATIE) study [110]. CATIE offered a head-to-head
comparison of FGAs and SGAs against a variety of treat-
ment outcome measures. Results to date found shown
only modest differences, a high dropout rate, and rather
limited effectiveness overall. The study's Principal Investi-
gator reflected on the findings and expressed the follow-
ing opinion:Implementation Science 2008, 3:13 http://www.implementationscience.com/content/3/1/13
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'The CATIE results suggest that first-generation antipsy-
chotics remain useful and deserve continued considera-
tion by clinicians and patients. This does not mean that
older, cheaper antipsychotics can replace more expensive
second-generation agents. It is crucial to point out that
equivalent does not mean identical: 25 percent of patients
may respond to risperidone and 25 percent to perphena-
zine, but they are not the same 25 percent. These initial
results from CATIE speak to the need for treatment
options – not restrictions, such as closed formularies or
fail-first requirements' [111].
If we construed guidelines as rules or performance stand-
ards, Lieberman's statement could be interpreted as reject-
ing their application to the treatment of schizophrenia
because there is an insufficient evidence base. Perhaps
instead, his reflection is a call to better assist clinicians in
making difficult decisions, precisely because the available
evidence is not determinative. If the latter interpretation
has merit, then Lieberman is affirming the value of assist-
ing physicians in how to use clinical guidelines without
following them blindly.
Services and implementation research have tended to
equate guidelines with EBPs, but this equation may be
premature if not misleading. At this stage of our knowl-
edge, particularly about severe mental illness, the two
remain distinct and appreciating their relationship may be
important to developing effective implementation strate-
gies. In the first place, guidelines serve multiple masters.
There is the evidence, of course. But several options that
are available any given decision point may qualify as 'evi-
dence-based.' Which option is recommended may
depend on factors such as cost, ease of administration,
effectiveness with the greatest number of patients, and
amenability to adjunctive or combination therapies.
Ironically, guidelines about implementation of evidence-
based practices may never have been scrutinized for effec-
tiveness or subjected to randomized trials. On some occa-
sions, guidelines are invoked to assist clinicians in
choosing among competing evidence-based treatment
options; at other times, they enable clinicians to veer must
off the clinical path and prescribe treatments in a manner
that has never been explicitly tested. For example, step
four of the TRS guideline calls for selection of a second
SGA; this choice is in lieu of clozapine, which is the med-
ication of choice at step five. Even though the efficacy of
second generation antipsychotic medications has been
well established by randomized control trials, their effec-
tiveness has not been demonstrated specifically for deci-
sions at step four of the TRS guideline – when patients
have not responded adequately to two trials of FGAs and
one trial of an SGA.
Despite its sensibility and its likeness to the PORT schizo-
phrenia guidelines, the TRS guideline is a novel applica-
tion that moves beyond the boundary of established and
demonstrably effective treatment. In this regard, TRS is
not the rule and not an exception. Expecting clinicians to
follow it, or the recommendations of a similar guideline,
automatically is tantamount to poor practice. But if the
guideline is incorporated into a decision strategy, it can
become a valuable means of transcending the dissemina-
tion gap and improving quality of care. Developing and
testing such a strategy is the principal task of phase two
and the subject of a separate report.
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